Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

RIPK3 Activation Leads to Cytokine Synthesis that Continues after Loss of Cell Membrane Integrity.

Orozco SL, Daniels BP, Yatim N, Messmer MN, Quarato G, Chen-Harris H, Cullen SP, Snyder AG, Ralli-Jain P, Frase S, Tait SWG, Green DR, Albert ML, Oberst A.

Cell Rep. 2019 Aug 27;28(9):2275-2287.e5. doi: 10.1016/j.celrep.2019.07.077.

2.

Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity.

Snyder AG, Hubbard NW, Messmer MN, Kofman SB, Hagan CE, Orozco SL, Chiang K, Daniels BP, Baker D, Oberst A.

Sci Immunol. 2019 Jun 21;4(36). pii: eaaw2004. doi: 10.1126/sciimmunol.aaw2004.

PMID:
31227597
3.

Comparing the effects of different cell death programs in tumor progression and immunotherapy.

Messmer MN, Snyder AG, Oberst A.

Cell Death Differ. 2019 Jan;26(1):115-129. doi: 10.1038/s41418-018-0214-4. Epub 2018 Oct 19.

PMID:
30341424
4.

β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.

Bucsek MJ, Qiao G, MacDonald CR, Giridharan T, Evans L, Niedzwecki B, Liu H, Kokolus KM, Eng JW, Messmer MN, Attwood K, Abrams SI, Hylander BL, Repasky EA.

Cancer Res. 2017 Oct 15;77(20):5639-5651. doi: 10.1158/0008-5472.CAN-17-0546. Epub 2017 Aug 17.

5.

HSPs drive dichotomous T-cell immune responses via DNA methylome remodelling in antigen presenting cells.

Kinner-Bibeau LB, Sedlacek AL, Messmer MN, Watkins SC, Binder RJ.

Nat Commun. 2017 May 31;8:15648. doi: 10.1038/ncomms15648.

6.

The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.

Netherby CS, Messmer MN, Burkard-Mandel L, Colligan S, Miller A, Cortes Gomez E, Wang J, Nemeth MJ, Abrams SI.

J Immunol. 2017 May 15;198(10):4129-4139. doi: 10.4049/jimmunol.1601722. Epub 2017 Mar 29.

7.

Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes.

Ku AW, Muhitch JB, Powers CA, Diehl M, Kim M, Fisher DT, Sharda AP, Clements VK, O'Loughlin K, Minderman H, Messmer MN, Ma J, Skitzki JJ, Steeber DA, Walcheck B, Ostrand-Rosenberg S, Abrams SI, Evans SS.

Elife. 2016 Dec 8;5. pii: e17375. doi: 10.7554/eLife.17375.

8.

Relevance of Interferon Regulatory Factor-8 Expression in Myeloid-Tumor Interactions.

Abrams SI, Netherby CS, Twum DY, Messmer MN.

J Interferon Cytokine Res. 2016 Jul;36(7):442-53. doi: 10.1089/jir.2015.0174. Review.

9.

Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.

Messmer MN, Netherby CS, Banik D, Abrams SI.

Cancer Immunol Immunother. 2015 Jan;64(1):1-13. doi: 10.1007/s00262-014-1639-3. Epub 2014 Nov 29. Review.

10.

Mild cold-stress depresses immune responses: Implications for cancer models involving laboratory mice.

Messmer MN, Kokolus KM, Eng JW, Abrams SI, Repasky EA.

Bioessays. 2014 Sep;36(9):884-91. doi: 10.1002/bies.201400066. Epub 2014 Jul 25. Review.

11.

Establishment of tumor-associated immunity requires interaction of heat shock proteins with CD91.

Zhou YJ, Messmer MN, Binder RJ.

Cancer Immunol Res. 2014 Mar;2(3):217-28. doi: 10.1158/2326-6066.CIR-13-0132. Epub 2013 Dec 31.

12.

Identification of the cellular sentinels for native immunogenic heat shock proteins in vivo.

Messmer MN, Pasmowitz J, Kropp LE, Watkins SC, Binder RJ.

J Immunol. 2013 Oct 15;191(8):4456-65. doi: 10.4049/jimmunol.1300827. Epub 2013 Sep 18.

13.

CD91-Dependent Modulation of Immune Responses by Heat Shock Proteins: A Role in Autoimmunity.

Binder RJ, Zhou YJ, Messmer MN, Pawaria S.

Autoimmune Dis. 2012;2012:863041. doi: 10.1155/2012/863041. Epub 2012 Nov 19.

14.

A role for the heat shock protein-CD91 axis in the initiation of immune responses to tumors.

Pawaria S, Messmer MN, Zhou YJ, Binder RJ.

Immunol Res. 2011 Aug;50(2-3):255-60. doi: 10.1007/s12026-011-8221-2.

Supplemental Content

Loading ...
Support Center